Adrenal Cortical Carcinoma-Review of Current Knowledge and Treatment Practices

Hematology/Oncology Clinics of North America

Volumn 21, Issue 3, 2007, Pages 489-507

  Phan, Alexandria T ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVIN; ALDOSTERONE; ANDROGEN; CISPLATIN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; HYDROCORTISONE; IRINOTECAN; MITOTANE; PREDNISONE; PROSTAGLANDIN E; PROTEIN P53; SOMATOMEDIN B; STREPTOZOCIN; SURAMIN; VASCULOTROPIN; VINCRISTINE;

ADRENAL CORTEX; ADRENAL CORTEX CARCINOMA; ADRENAL GLAND; ADRENAL INCIDENTALOMA; ADRENAL INSUFFICIENCY; ADRENALECTOMY; BLOOD CLOTTING DISORDER; BLOOD TOXICITY; BONE MARROW TOXICITY; CANCER STAGING; CANCER SUSCEPTIBILITY; CARDIOMYOPATHY; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL FEATURE; COMBINATION CHEMOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; DIARRHEA; DRUG DOSE TITRATION; DRUG HALF LIFE; DRUG MECHANISM; ECHOGRAPHY; GASTROINTESTINAL SYMPTOM; GENE MUTATION; GENE OVEREXPRESSION; HORMONE RELEASE; HUMAN; INCIDENCE; MALAISE; MONOTHERAPY; NAUSEA; NAUSEA AND VOMITING; NEUROPSYCHIATRIC TOXICITY; NEUROTOXICITY; NEUTROPENIA; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; RECOMMENDED DRUG DOSE; REVIEW; THROMBOCYTOPENIA; VOMITING;

ADRENAL GLAND NEOPLASMS; HUMANS; NEOPLASM STAGING; PROGNOSIS;

EID: 34249811195     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hoc.2007.04.007     Document Type: Review

References (112)

1. Barzon L., Sonino N., Fallo F., et al. Prevalence and natural history of adrenal incidentalomas. Eur J Endocrinol 149 4 (2003) 273-285
2. Siren J.E., Haapiainen R.K., Huikuri K.T., et al. Incidentalomas of the adrenal gland: 36 operated patients and review of literature. World J Surg 17 5 (1993) 634-639
3. Copeland P.M. The incidentally discovered adrenal mass. Ann Intern Med 98 6 (1983) 940-945
4. Plager J.E. Carcinoma of the adrenal cortex: clinical description, diagnosis, and treatment. Int Adv Surg Oncol 7 (1984) 329-353
5. Brennan M.F. Adrenocortical carcinoma. CA Cancer J Clin 37 6 (1987) 348-365
6. Javadpour N., Woltering E.A., and Brennan M.F. Adrenal neoplasms. Curr Probl Surg 17 1 (1980) 1-52
7. Wooten M.D., and King D.K. Adrenal cortical carcinoma. Epidemiology and treatment with mitotane and a review of the literature. Cancer 72 11 (1993) 3145-3155
8. Dackiw A.P., Lee J.E., Gagel R.F., et al. Adrenal cortical carcinoma. World J Surg 25 7 (2001) 914-926
9. Venkatesh S., Hickey R.C., Sellin R.V., et al. Adrenal cortical carcinoma. Cancer 64 3 (1989) 765-769
10. Vassilopoulou-Sellin R., and Schultz P.N. Adrenocortical carcinoma. Clinical outcome at the end of the 20th century. Cancer 92 5 (2001) 1113-1121
11. Soreide J.A., Brabrand K., and Thoresen S.O. Adrenal cortical carcinoma in Norway, 1970-1984. World J Surg 16 4 (1992) 663-667 [discussion: 668]
12. Schulick R.D., and Brennan M.F. Adrenocortical carcinoma. World J Urol 17 1 (1999) 26-34
13. Pommier R.F., and Brennan M.F. An eleven-year experience with adrenocortical carcinoma. Surgery 112 6 (1992) 963-970 [discussion: 970-1]
14. Luton J.P., Cerdas S., Billaud L., et al. Clinical features of adrenocortical carcinoma, prognostic factors, and the effect of mitotane therapy. N Engl J Med 322 17 (1990) 1195-1201
15. Icard P., Goudet P., Charpenay C., et al. Adrenocortical carcinomas: surgical trends and results of a 253-patient series from the French Association of Endocrine Surgeons study group. World J Surg 25 7 (2001) 891-897
16. Haak H.R., Hermans J., van de Velde C.J., et al. Optimal treatment of adrenocortical carcinoma with mitotane: results in a consecutive series of 96 patients. Br J Cancer 69 5 (1994) 947-951
17. Hutter Jr. A.M., and Kayhoe D.E. Adrenal cortical carcinoma. Clinical features of 138 patients. Am J Med 41 4 (1966) 572-580
18. Wagner J., Portwine C., Rabin K., et al. High frequency of germline p53 mutations in childhood adrenocortical cancer. J Natl Cancer Inst 86 22 (1994) 1707-1710
19. Varley J.M., McGown G., Thorncroft M., et al. Are there low-penetrance TP53 alleles? Evidence from childhood adrenocortical tumors. Am J Hum Genet 65 4 (1999) 995-1006
20. Ribeiro R.C., Sandrini F., Figueiredo B., et al. An inherited p53 mutation that contributes in a tissue-specific manner to pediatric adrenal cortical carcinoma. Proc Natl Acad Sci U S A 98 16 (2001) 9330-9335
21. Li F.P., and Fraumeni Jr. J.F. Rhabdomyosarcoma in children: epidemiologic study and identification of a familial cancer syndrome. J Natl Cancer Inst 43 6 (1969) 1365-1373
22. DiGiammarion E.L., Lee A.S., Cadwell C., et al. A novel mechanism of tumorigenesis involving pH-dependent destabilization of a mutant p53 tetramer. Nat Struct Biol 9 1 (2002) 12-16
23. Schulte K.M., Mengel M., Heinze M., et al. Complete sequencing and messenger ribonucleic acid expression analysis of the MEN I gene in adrenal cancer. J Clin Endocrinol Metab 85 1 (2000) 441-448
24. Kjellman M., Roshani L., Teh B.T., et al. Genotyping of adrenocortical tumors: very frequent deletions of the MEN1 locus in 11q13 and of a 1-centimorgan region in 2p16. J Clin Endocrinol Metab 84 2 (1999) 730-735
25. Heppner C., Reineke M., Agarwal S.K., et al. MEN1 gene analysis in sporadic adrenocortical neoplasms. J Clin Endocrinol Metab 84 1 (1999) 216-219
26. Rosenberg D., Groussin L., Jullian E., et al. Transcription factor 3',5'-cyclic adenosine 5'-monophosphate-responsive element-binding protein (CREB) is decreased during human adrenal cortex tumorigenesis and fetal development. J Clin Endocrinol Metab 88 8 (2003) 3958-3965
27. Groussin L., Krischner L.S., Vincent-Dejean C., et al. Molecular analysis of the cyclic AMP-dependent protein kinase A (PKA) regulatory subunit 1A (PRKAR1A) gene in patients with Carney complex and primary pigmented nodular adrenocortical disease (PPNAD) reveals novel mutations and clues for pathophysiology: augmented PKA signaling is associated with adrenal tumorigenesis in PPNAD. Am J Hum Genet 71 6 (2002) 1433-1442
28. Groussin L., Jullian E., Perlemoinc K., et al. Mutations of the PRKAR1A gene in Cushing's syndrome due to sporadic primary pigmented nodular adrenocortical disease. J Clin Endocrinol Metab 87 9 (2002) 4324-4329
29. Ilvesmaki V., Kahri A.I., Miettinen P.J., et al. Insulin-like growth factors (IGFs) and their receptors in adrenal tumors: high IGF-II expression in functional adrenocortical carcinomas. J Clin Endocrinol Metab 77 3 (1993) 852-858
30. Hertel N.T., Carlsen N., Kerndrup G., et al. Late relapse of adrenocortical carcinoma in Beckwith-Wiedemann syndrome. Clinical, endocrinological and genetic aspects. Acta Paediatr 92 4 (2003) 439-443
31. Gicquel C., Raffin-Sanson M.L., Gaston V., et al. Structural and functional abnormalities at 11p15 are associated with the malignant phenotype in sporadic adrenocortical tumors: study on a series of 82 tumors. J Clin Endocrinol Metab 82 8 (1997) 2559-2565
32. Gicquel C., Bertagna X., Gaston V., et al. Molecular markers and long-term recurrences in a large cohort of patients with sporadic adrenocortical tumors. Cancer Res 61 18 (2001) 6762-6767
33. Mesiano S., Mellon S.H., and Jaffe R.B. Mitogenic action, regulation, and localization of insulin-like growth factors in the human fetal adrenal gland. J Clin Endocrinol Metab 76 4 (1993) 968-976
34. Gicquel C., Boulle N., Logie A., et al. [Involvement of the IGF system in the pathogenesis of adrenocortical tumors]. Ann Endocrinol (Paris) 62 2 (2001) 189-192 [in French]
35. Gicquel C., Bertagna X., Schncid H., et al. Rearrangements at the 11p15 locus and overexpression of insulin-like growth factor-II gene in sporadic adrenocortical tumors. J Clin Endocrinol Metab 78 6 (1994) 1444-1453
36. Gicquel C., Bertagna X., and Le Bouc Y. Recent advances in the pathogenesis of adrenocortical tumours. Eur J Endocrinol 133 2 (1995) 133-144
37. Yano T., Linchan M., Anglard P., et al. Genetic changes in human adrenocortical carcinomas. J Natl Cancer Inst 81 7 (1989) 518-523
38. Sarkaria I.S., Stojadinovic A., Talbot S.G., et al. Squamous cell carcinoma-related oncogene is highly expressed in developing, normal, and adenomatous adrenal tissue but not in aggressive adrenocortical carcinomas. Surgery 136 6 (2004) 1122-1128
39. Beuschlein F., Looyenga B.D., Reincke M., et al. Role of the inhibin/activin system and luteinizing hormone in adrenocortical tumorigenesis. Horm Metab Res 36 6 (2004) 392-396
40. Zacharicva S., Atanassova I., Orbetzova M., et al. Circulating vascular endothelial growth factor and active renin concentrations and prostaglandin E2 urinary excretion in patients with adrenal tumours. Eur J Endocrinol 150 3 (2004) 345-349
41. Kolomecki K., Stepien I.I., Barlos M., et al. Usefulness of VEGF, MMP-2, MMP-3 and TIMP-2 serum level evaluation in patients with adrenal tumours. Endocr Regul 35 1 (2001) 9-16
42. Zhao J., Speel E.J., Muletta-Feurer S., et al. Analysis of genomic alterations in sporadic adrenocortical lesions. Gain of chromosome 17 is an early event in adrenocortical tumorigenesis. Am J Pathol 155 4 (1999) 1039-1045
43. Kjellman M., Kallionicmi O.P., Karhu R., et al. Genetic aberrations in adrenocortical tumors detected using comparative genomic hybridization correlate with tumor size and malignancy. Cancer Res 56 18 (1996) 4219-4223
44. Dohna M., Reincke M., Mincheva A., et al. Adrenocortical carcinoma is characterized by a high frequency of chromosomal gains and high-level amplifications. Genes Chromosomes Cancer 28 2 (2000) 145-152
45. Beuschlcin F., Reincke M., Karl M., et al. Clonal composition of human adrenocortical neoplasms. Cancer Res 54 18 (1994) 4927-4932
46. Ng L., and Libertino J.M. Adrenocortical carcinoma: diagnosis, evaluation and treatment. J Urol 169 1 (2003) 5-11
47. Crucitti F., Bellantone R., Ferrante A., et al. The Italian Registry for Adrenal Cortical Carcinoma: analysis of a multiinstitutional series of 129 patients. The ACC Italian Registry Study Group. Surgery 119 2 (1996) 161-170
48. Wajchenberg B.L., Albergaria Pereira M.A., Mcdonca B.B., et al. Adrenocortical carcinoma: clinical and laboratory observations. Cancer 88 4 (2000) 711-736
49. Fassnacht M., Kenn W., and Allolio B. Adrenal tumors: how to establish malignancy?. J Endocrinol Invest 27 4 (2004) 387-399
50. Weiss L.M., Medeiros L.J., and Vickery Jr. A.L. Pathologic features of prognostic significance in adrenocortical carcinoma. Am J Surg Pathol 13 3 (1989) 202-206
51. Fuhrman S.A., Lasky L.C., and Limas C. Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol 6 7 (1982) 655-663
52. Wachenfeld C., Beuschlein F., Zwermann O., et al. Discerning malignancy in adrenocortical tumors: are molecular markers useful?. Eur J Endocrinol 145 3 (2001) 335-341
53. Vargas M.P., Vargas H.I., Kleiner D.E., et al. Adrenocortical neoplasms: role of prognostic markers MIB-1, P53, and RB. Am J Surg Pathol 21 5 (1997) 556-562
54. Terzolo M., Boccuzzi A., Bovio S., et al. Immunohistochemical assessment of Ki-67 in the differential diagnosis of adrenocortical tumors. Urology 57 1 (2001) 176-182
55. Saeger W. Histopathological classification of adrenal tumours. Eur J Clin Invest 30 Suppl 3 (2000) 58-62
56. Goldblum J.R., Shannon R., Kaldjian E.P., et al. Immunohistochemical assessment of proliferative activity in adrenocortical neoplasms. Mod Pathol 6 6 (1993) 663-668
57. Busam K.J., Iversen K., Coplan K.A., et al. Immunoreactivity for A103, an antibody to melan-A (Mart-1), in adrenocortical and other steroid tumors. Am J Surg Pathol 22 1 (1998) 57-63
58. Saeger W. High diagnostic accuracy of adrenal core biopsy: results of the German and Austrian adrenal network multicenter trial in 220 consecutive patients. Hum Pathol 34 2 (2003) 180-186
59. Tissier F., Louvel A., Grabar S., et al. Cyclin E correlates with malignancy and adverse prognosis in adrenocortical tumors. Eur J Endocrinol 150 6 (2004) 809-817
60. NIH state-of-the-science statement on management of the clinically inapparent adrenal mass ("incidentaloma"). NIH Consens State Sci Statements 19 2 (2002) 1-25
61. Boland G.W., Lee M.J., Gazelle G.S., et al. Characterization of adrenal masses using unenhanced CT: an analysis of the CT literature. AJR Am J Roentgenol 171 1 (1998) 201-204
62. Caoili E.M., Korobkin M., Francis I.R., et al. Delayed enhanced CT of lipid-poor adrenal adenomas. AJR Am J Roentgenol 175 5 (2000) 1411-1415
63. Caoili E.M., Korobkin M., Francis I.R., et al. Adrenal masses: characterization with combined unenhanced and delayed enhanced CT. Radiology 222 3 (2002) 629-633
64. Korobkin M., Brodeur F.J., Francis I.R., et al. CT time-attenuation washout curves of adrenal adenomas and nonadenomas. AJR Am J Roentgenol 170 3 (1998) 747-752
65. Lee J.E., Berger D.H., el-Naggar A.K., et al. Surgical management, DNA content, and patient survival in adrenal cortical carcinoma. Surgery 118 6 (1995) 1090-1098
66. Pena C.S., et al. Characterization of indeterminate (lipid-poor) adrenal masses: use of washout characteristics at contrast-enhanced CT. Radiology 217 3 (2000) 798-802
67. Szolar D.H., and Kammerhuber F.H. Adrenal adenomas and nonadenomas: assessment of washout at delayed contrast-enhanced CT. Radiology 207 2 (1998) 369-375
68. Szolar D.H., Korobkin M., Reittner P., et al. Adrenocortical carcinomas and adrenal pheochromocytomas: mass and enhancement loss evaluation at delayed contrast-enhanced CT. Radiology 234 2 (2005) 479-485
69. Korobkin M., Giordano T.J., Brodeur F.J., et al. Adrenal adenomas: relationship between histologic lipid and CT and MR findings. Radiology 200 3 (1996) 743-747
70. Outwater E.K., Siegelman E.S., Huang A.B., et al. Adrenal masses: correlation between CT attenuation value and chemical shift ratio at MR imaging with in-phase and opposed-phase sequences. Radiology 200 3 (1996) 749-752
71. Boland G.W., Goldberg M.A., Lee M.J., et al. Indeterminate adrenal mass in patients with cancer: evaluation at PET with 2-[F-18]-fluoro-2-deoxy-D-glucose. Radiology 194 1 (1995) 131-134
72. Maurca S., Mainolfi C., Bazzicalupo L., et al. Imaging of adrenal tumors using FDG PET: comparison of benign and malignant lesions. AJR Am J Roentgenol 173 1 (1999) 25-29
73. Yun M., Kim W., Alnafisi N., et al. 18F-FDG PET in characterizing adrenal lesions detected on CT or MRI. J Nucl Med 42 12 (2001) 1795-1799
74. Mackie G.C., Shulkin B.L., Ribeiro R.C., et al. Use of [18F]fluorodeoxyglucose positron emission tomography in evaluating locally recurrent and metastatic adrenocortical carcinoma. J Clin Endocrinol Metab 91 7 (2006) 2665-2671
75. Bergstrom M., Juhlin C., Bonascra T.A., et al. PET imaging of adrenal cortical tumors with the 11beta-hydroxylase tracer 11C-metomidate. J Nucl Med 41 2 (2000) 275-282
76. Khan T.S., et al. 11C-metomidate PET imaging of adrenocortical cancer. Eur J Nucl Med Mol Imaging 30 3 (2003) 403-410
77. Macfarlane D.A. Cancer of the adrenal cortex; the natural history, prognosis and treatment in a study of fifty-five cases. Ann R Coll Surg Engl 23 3 (1958) 155-186
78. Sullivan M., Boileau M., and Hodges C.V. Adrenal cortical carcinoma. J Urol 120 6 (1978) 660-665
79. Icard P., Chapuis Y., Andreassian B., et al. Adrenocortical carcinoma in surgically treated patients: a retrospective study on 156 cases by the French Association of Endocrine Surgery. Surgery 112 6 (1992) 972-979 [discussion: 979-80]
80. Schulick R.D., and Brennan M.F. Long-term survival after complete resection and repeat resection in patients with adrenocortical carcinoma. Ann Surg Oncol 6 8 (1999) 719-726
81. Bertagna C., and Orth D.N. Clinical and laboratory findings and results of therapy in 58 patients with adrenocortical tumors admitted to a single medical center (1951 to 1978). Am J Med 71 5 (1981) 855-875
82. Stojadinovic A., Ghossein R.A., Hoos A., et al. Adrenocortical carcinoma: clinical, morphologic, and molecular characterization. J Clin Oncol 20 4 (2002) 941-950
83. Zografos G.C., Driscoll D.L., Karakousis C.P., et al. Adrenal adenocarcinoma: a review of 53 cases. J Surg Oncol 55 3 (1994) 160-164
84. Cobb W.S., Kercher K.W., Sing R.F., et al. Laparoscopic adrenalectomy for malignancy. Am J Surg 189 4 (2005) 405-411
85. Gonzalez R.J., Shapiro S., Sarlis N., et al. Laparoscopic resection of adrenal cortical carcinoma: a cautionary note. Surgery 138 6 (2005) 1078-1085 [discussion: 1085-6]
86. Harrison L.E., Gaudin P.B., and Brennan M.F. Pathologic features of prognostic significance for adrenocortical carcinoma after curative resection. Arch Surg 134 2 (1999) 181-185
87. Grondal S., Cedermark B., Eriksson B., et al. Adrenocortical carcinoma. A retrospective study of a rare tumor with a poor prognosis. Eur J Surg Oncol 16 6 (1990) 500-506
88. Hogan T.F., Gilchrist K.W., Westring D.W., et al. A clinical and pathological study of adrenocortical carcinoma: therapeutic implications. Cancer 45 11 (1980) 2880-2883
89. Fassnacht M., et al. Efficacy of adjuvant radiotherapy of the tumor bed on local recurrence of adrenocortical carcinoma. J Clin Endocrinol Metab 91 11 (2006) 4501-4504
90. Hutter Jr. A.M., and Kayhoe D.E. Adrenal cortical carcinoma. Results of treatment with o,p'DDD in 138 patients. Am J Med 41 4 (1966) 581-592
91. Lubitz J.A., Freeman L., and Okun R. Mitotane use in inoperable adrenal cortical carcinoma. JAMA 223 10 (1973) 1109-1112
92. Schteingart D.F., Motazedi A., Noonan R.A., et al. Treatment of adrenal carcinomas. Arch Surg 117 9 (1982) 1142-1146
93. Baudin E., Pellegriti G., Bonnay M., et al. Impact of monitoring plasma 1,1-dichlorodiphenildichloroethane (o,p'DDD) levels on the treatment of patients with adrenocortical carcinoma. Cancer 92 6 (2001) 1385-1392
94. Decker R.A., Elson P., Hogan T.F., et al. Eastern Cooperative Oncology Group study 1879: mitotane and Adriamycin in patients with advanced adrenocortical carcinoma. Surgery 110 6 (1991) 1006-1013
95. Haak H.R., Caekebeke-Peerlinck K.M., van Scters A.P., et al. Prolonged bleeding time due to mitotane therapy. Eur J Cancer 27 5 (1991) 638-641
96. Henley D.J., Van Heerden J.A., Grant C.S., et al. Adrenal cortical carcinoma-a continuing challenge. Surgery 94 6 (1983) 926-931
97. Kasperlik-Zaluska A.A. Clinical results of the use of mitotane for adrenocortical carcinoma. Braz J Med Biol Res 33 10 (2000) 1191-1196
98. van Slooten H., Moolenaar A.J., van Seters A.P., et al. The treatment of adrenocortical carcinoma with o,p'-DDD: prognostic implications of serum level monitoring. Eur J Cancer Clin Oncol 20 1 (1984) 47-53
99. Abraham J., Bakke S., Rutt A., et al. A phase II trial of combination chemotherapy and surgical resection for the treatment of metastatic adrenocortical carcinoma: continuous infusion doxorubicin, vincristine, and etoposide with daily mitotane as a P-glycoprotein antagonist. Cancer 94 9 (2002) 2333-2343
100. Berruti A., Terzolo M., Pia A., et al. Mitotane associated with etoposide, doxorubicin, and cisplatin in the treatment of advanced adrenocortical carcinoma. Italian Group for the Study of Adrenal Cancer. Cancer 83 10 (1998) 2194-2200
101. Bonacci R., Gigliotti A., Baudin E., et al. Cytotoxic therapy with etoposide and cisplatin in advanced adrenocortical carcinoma. Reseau Comete INSERM. Br J Cancer 78 4 (1998) 546-549
102. Bukowski R.M., Woflc M., Levine H.S., et al. Phase II trial of mitotane and cisplatin in patients with adrenal carcinoma: a Southwest Oncology Group study. J Clin Oncol 11 1 (1993) 161-165
103. Khan T.S., Imam H., Juhlin C., et al. Streptozocin and o,p'DDD in the treatment of adrenocortical cancer patients: long-term survival in its adjuvant use. Ann Oncol 11 10 (2000) 1281-1287
104. Berruli A., Sperone P., Daffara F., et al. Adjuvant mitotane therapy for adreno-cortical carcinoma. [abstract]. J Clin Oncol 23 16S, part 1 (2005) 4570
105. Dickstein G., Shcchner C., Daffara F., et al. Is there a role for low doses of mitotane (o,p'-DDD) as adjuvant therapy in adrenocortical carcinoma?. J Clin Endocrinol Metab 83 9 (1998) 3100-3103
106. Vassilopoulou-Sellin R., Guinee V.F., Klein M.J., et al. Impact of adjuvant mitotane on the clinical course of patients with adrenocortical cancer. Cancer 71 10 (1993) 3119-3123
107. Heilmann P., Wagner P., Nawroth P.P., et al. [Therapy of the adrenocortical carcinoma with Lysodren (o,p'-DDD). Therapeutic management by monitoring o,p'-DDD blood levels]. Med Klin (Munich) 96 7 (2001) 371-377 [in German]
108. Schlumberger M., Brugieres L., Gicquel C., et al. 5-Fluorouracil, doxorubicin, and cisplatin as treatment for adrenal cortical carcinoma. Cancer 67 12 (1991) 2997-3000
109. van Slooten H., and van Oosterom A.T. CAP (cyclophosphamide, doxorubicin, and cisplatin) regimen in adrenal cortical carcinoma. Cancer Treat Rep 67 4 (1983) 377-379
110. Williamson S.K., Lew D., Miller G.J., et al. Phase II evaluation of cisplatin and etoposide followed by mitotane at disease progression in patients with locally advanced or metastatic adrenocortical carcinoma: a Southwest Oncology Group Study. Cancer 88 5 (2000) 1159-1165
111. Baudin E., Docao C., Gicquel C., et al. Use of a topoisomerase I inhibitor (irinotecan, CPT-11) in metastatic adrenocortical carcinoma. Ann Oncol 13 11 (2002) 1806-1809
112. La Rocca R.V., Stein C.A., Danesi R., et al. Suramin in adrenal cancer: modulation of steroid hormone production, cytotoxicity in vitro, and clinical antitumor effect. J Clin Endocrinol Metab 71 2 (1990) 497-504